|
1
|
Mellstedt H, Vansteenkiste J and Thatcher
N: Vaccines for the treatment of non-small cell lung cancer:
Investigational approaches and clinical experience. Lung Cancer.
73:11–17. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gardner A and Ruffell B: Dendritic cells
and cancer immunity. Trends Immunol. 37:855–865. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
González FE, Gleisner A, Falcón-Beas F,
Osorio F, López MN and Salazar-Onfray F: Tumor cell lysates as
immunogenic sources for cancer vaccine design. Hum Vaccines
Immunother. 10:3261–3269. 2014. View Article : Google Scholar
|
|
5
|
Ilett E, Prestwich R and Melcher A: The
evolving role of dendritic cells in cancer therapy. Expert Opin
Biol Ther. 10:369–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bol KF, Schreibelt G, Gerritsen WR, De
Vries IJM and Figdor CG: Dendritic cell-based immunotherapy: State
of the art and beyond. Clin Cancer Res. 22:1897–1906. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kadowaki N, Ho S, Antonenko S, Malefyt R,
Kastelein R, Bazan F and Liu Y: Subsets of human dendritic cell
precursors express different toll-like receptors and respond to
different microbial antigens. J Exp Med. 194:863–869. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Swiecki M and Colonna M: The multifaceted
biology of plasmacytoid dendritic cells. Nat Rev Immunol.
15:471–485. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nizzoli G, Krietsch J, Weick A,
Steinfelder S, Facciotti F, Gruarin P, Bianco A, Steckel B, Moro M,
Crosti M, et al: Human CD1c+ dendritic cells secrete
high levels of IL-12 and potently prime cytotoxic T-cell responses.
Blood. 122:932–942. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lou Y, Liu C, Kim GJ, Liu YJ, Hwu P and
Wang G: Plasmacytoid dendritic cells synergize with myeloid
dendritic cells in the induction of antigen-specific antitumor
immune responses. J Immunol. 178:1534–1541. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mocellin S, Mandruzzato S, Bronte V, Lise
M and Nitti D: Part I: Vaccines for solid tumours. Lancet Oncol.
5:681–689. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schuler G, Schuler-Thurner B and Steinman
RM: The use of dendritic cells in cancer immunotherapy. Curr Opin
Immunol. 15:138–147. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tagliamonte M, Petrizzo A, Tornesello ML,
Buonaguro FM and Buonaguro L: Antigen-specific vaccines for cancer
treatment. Hum Vaccines Immunother. 10:3332–3346. 2014. View Article : Google Scholar
|
|
14
|
Ridolfi R, Petrini M, Fiammenghi L,
Stefanelli M, Ridolfi L, Ballardini M, Migliori G and Riccobon A:
Improved overall survival in dendritic cell vaccination-induced
immunoreactive subgroup of advanced melanoma patients. J Transl
Med. 4:362006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Trefzer U, Herberth G, Wohlan K, Milling
A, Thiemann M, Sharav T, Sparbier K, Sterry W and Walden P:
Tumour-dendritic hybrid cell vaccination for the treatment of
patients with malignant melanoma: Immunological effects and
clinical results. Vaccine. 23:2367–2373. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nagayama H, Sato K, Morishita M, Uchimaru
K, Oyaizu N, Inazawa T, Yamasaki T, Enomoto M, Nakaoka T, Nakamura
T, et al: Results of a phase I clinical study using autologous
tumour lysate-pulsed monocyte-derived mature dendritic cell
vaccinations for stage IV malignant melanoma patients combined with
low dose interleukin-2. Melanoma Res. 13:521–530. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hersey P, Menzies SW, Halliday GM, Nguyen
T, Farrelly ML, DeSilva C and Lett M: Phase I/II study of treatment
with dendritic cell vaccines in patients with disseminated
melanoma. Cancer Immunol Immunother. 53:125–134. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jouanneau E, Poujol D, Gulia S, Le Mercier
I, Blay JY, Belin MF and Puisieux I: Dendritic cells are essential
for priming but inefficient for boosting antitumour immune response
in an orthotopic murine glioma model. Cancer Immunol Immunother.
55:254–267. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Y, Yoneyama H, Wang Y, Ishikawa S,
Hashimoto S, Gao JL, Murphy P and Matsushima K: Mobilization of
dendritic cell precursors into the circulation by administration of
MIP-1alpha in mice. J Natl Cancer Inst. 96:201–209. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hatfield P, Merrick AE, West E, ODonnell
D, Selby P, Vile R and Melcher AA: Optimization of dendritic cell
loading with tumor cell lysates for cancer immunotherapy. J
Immunother. 31:620–632. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim HS, Choo YS, Koo T, Bang S, Oh TY, Wen
J and Song SY: Enhancement of antitumor immunity of dendritic cells
pulsed with heat-treated tumor lysate in murine pancreatic cancer.
Immunol Lett. 103:142–148. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qiu J, Li GW, Sui YF, Song HP, Si SY and
Ge W: Heat-shocked tumor cell lysate-pulsed dendritic cells induce
effective anti-tumor immune response in vivo. World J
Gastroenterol. 12:473–478. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Castelli C, Rivoltini L, Rini F, Belli F,
Testori A, Maio M, Mazzaferro V, Coppa J, Srivastava PK and
Parmiani G: Heat shock proteins: Biological functions and clinical
application as personalized vaccines for human cancer. Cancer
Immunol Immunother. 53:227–233. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pelleitier M and Montplaisir S: The nude
mouse: A model of deficient T-cell function. Methods Achiev Exp
Pathol. 7:149–166. 1975.PubMed/NCBI
|
|
25
|
Alberts B, Johnson A and Lewis J: Helper T
cells and lymphocyte activation. Molecular Biology of the Cell.
1–8. 2002.PubMed/NCBI
|
|
26
|
Zhang Y, Zhang N, Zhao M and Hoffman RM:
Comparison of the selective targeting efficacy of Salmonella
typhimurium A1-R and VNP20009 on the Lewis lung carcinoma in
nude mice. Oncotarget. 6:14625–14631. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fu Q, Wu Y, Yan F, Wang N, Wang W, Cao X,
Wang Y and Wan T: Efficient induction of a Her2-specific anti-tumor
response by dendritic cells pulsed with a Hsp70L1-Her2 341–456
fusion protein. Cell Mol Immunol. 8:424–432. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Song S, Zhang K, You H, Wang J, Wang Z,
Yan C and Liu F: Significant anti-tumour activity of adoptively
transferred T cells elicited by intratumoral dendritic cell vaccine
injection through enhancing the ratio of CD8+ T
cell/regulatory T cells in tumour. Clin Exp Immunol. 162:75–83.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Piccioli D, Tavarini S, Borgogni E, Steri
V, Nuti S, Sammicheli C, Bardelli M, Montagna D, Locatelli F and
Wack A: Functional specialization of human circulating CD16 and
CD1c myeloid dendritic-cell subsets. Blood. 109:5371–5379. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Audiger C, Rahman MJ, Yun TJ, Tarbell KV
and Lesage S: The importance of dendritic cells in maintaining
immune tolerance. J Immunol. 198:2223–2231. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu J, Cao S, Kim S, Chung EY, Homma Y,
Guan X, Jimenez V and Ma X: Interleukin-12: An update on its
immunological activities, signaling and regulation of gene
expression. Curr Immunol Rev. 1:119–137. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Blanco P, Palucka AK, Pascual V and
Banchereau J: Dendritic cells and cytokines in human inflammatory
and autoimmune diseases. Cytokine Growth Factor Rev. 19:41–52.
2008. View Article : Google Scholar : PubMed/NCBI
|
